Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Global LEADERS Trial: head-to-head comparison of a biodegradeable polymer Biolimus A9 eluting stent (BioMatrix Flex) and a durable polymer drug-eluting stent

Next Previous
Trial Profile

Global LEADERS Trial: head-to-head comparison of a biodegradeable polymer Biolimus A9 eluting stent (BioMatrix Flex) and a durable polymer drug-eluting stent

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ticagrelor (Primary) ; Umirolimus (Primary) ; Antiplatelets; Aspirin
  • Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis; Myocardial infarction; Myocardial ischaemia; Stroke; Thrombosis
  • Focus Therapeutic Use
  • Acronyms Global LEADERS; LEADERS-II

Most Recent Events

  • 01 Oct 2021 Results (n=6594) of sub-group analysis validating value of GRACE risk score in ACS patients of contemporary PCI era and assessing interaction between patient stratification according to GRACE risk score and antiplatelet treatment strategy published in the Catheterization and Cardiovascular Interventions
  • 17 Nov 2020 Results of pooled analysis from five trials (GLOBAL LEADERS, STOP-DAPT2, SMART-CHOICE, TWIGHLIGHT and TICO) presented at the American Heart Association Scientific Sessions 2020
  • 01 Jun 2020 Status has been changed to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top